These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 25739418)

  • 21. Trastuzumab before breast surgery? Large trial says yes but does not quell debate.
    Rowan K
    J Natl Cancer Inst; 2009 Apr; 101(7):448-9. PubMed ID: 19318626
    [No Abstract]   [Full Text] [Related]  

  • 22. Phase II study of neoadjuvant pegylated liposomal doxorubicin and cyclophosphamide ± trastuzumab followed by docetaxel in locally advanced breast cancer.
    Tuxen MK; Cold S; Tange UB; Balslev E; Nielsen DL
    Acta Oncol; 2014 Oct; 53(10):1440-5. PubMed ID: 24991893
    [No Abstract]   [Full Text] [Related]  

  • 23. [Use of Taxotere in neoadjuvant therapy of breast cancer].
    Semiglazov VV; Donskikh RV; Semiglazova TIu; Bozhok AA; Matsko DE
    Vopr Onkol; 2011; 57(5):645-50. PubMed ID: 22238937
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of HER2-positive breast cancer: looking backwards briefly.
    Puhalla S; Brufsky A
    Lancet Oncol; 2013 Dec; 14(13):1250-1. PubMed ID: 24239207
    [No Abstract]   [Full Text] [Related]  

  • 25. [No addition benefit from coadministration of trastuzumab and anthracyclines].
    Wilhelm M
    Strahlenther Onkol; 2014 Apr; 190(4):428-9. PubMed ID: 24638245
    [No Abstract]   [Full Text] [Related]  

  • 26. [BREAST-CONSERVING SURGERY AFTER NEOADJUVANT THERAPY FOR BREAST CANCER].
    Semiglazov VF; Semiglazov VV; Petrenko OL; Komyakhov AV; Dashyan GA; Paltuev RM; Semiglazova TY; Manikhas AG; Bozhok AA; Lalak IA
    Vopr Onkol; 2015; 61(3):381-6. PubMed ID: 26242149
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
    Gianni L; Pienkowski T; Im YH; Roman L; Tseng LM; Liu MC; Lluch A; Staroslawska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi G; Szado T; Ratnayake J; Ross G; Valagussa P
    Lancet Oncol; 2012 Jan; 13(1):25-32. PubMed ID: 22153890
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Weighing the options for human epidermal growth factor receptor 2-directed therapy in metastatic breast cancer.
    Lin NU
    J Clin Oncol; 2015 May; 33(14):1530-3. PubMed ID: 25847924
    [No Abstract]   [Full Text] [Related]  

  • 29. High pathologic complete response in HER 2-positive locally advanced breast cancer after primary systemic chemotherapy with weekly docetaxel and epirubicin.
    Chen SC; Chang HK; Lin YC; Hsueh S; Cheung YC; Leung WM; Tsai CS; Lo YF; Tsai HP; Shen SC; Chen MF
    Jpn J Clin Oncol; 2008 Feb; 38(2):99-105. PubMed ID: 18270380
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Practice and consideration on neoadjuvant therapy for early breast cancer].
    Song ST
    Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):555-7. PubMed ID: 21029704
    [No Abstract]   [Full Text] [Related]  

  • 31. A 35-Year-Old Woman With a Change in HER2 Expression Following Neoadjuvant Chemotherapy for Invasive Breast Cancer.
    Stoen E; Kabos P; Borden KC; Brown RJ; Borges VF; Diamond JR
    Oncology (Williston Park); 2018 Jun; 32(6):298-302. PubMed ID: 29940061
    [No Abstract]   [Full Text] [Related]  

  • 32. Herceptin (trastuzumab): adjuvant and neoadjuvant trials.
    Yaal-Hahoshen N; Safra T
    Isr Med Assoc J; 2006 Jun; 8(6):416-21. PubMed ID: 16833172
    [No Abstract]   [Full Text] [Related]  

  • 33. [Systemic pharmacotherapy in breast cancer].
    Boér K
    Orv Hetil; 2004 Jan; 145(4):187-92. PubMed ID: 14978885
    [No Abstract]   [Full Text] [Related]  

  • 34. COUNTERPOINT: HER2-Targeted Combinations in Advanced HER2-Positive Breast Cancer.
    Pegram MD
    Oncology (Williston Park); 2015 Nov; 29(11):797, 801-2. PubMed ID: 26573059
    [No Abstract]   [Full Text] [Related]  

  • 35. Reply to L. Cabel et al.
    Fehrenbacher L; Capra A; Habel L
    J Clin Oncol; 2015 Jan; 33(3):292-3. PubMed ID: 25512452
    [No Abstract]   [Full Text] [Related]  

  • 36. HER2-positive breast cancer.
    Loibl S; Gianni L
    Lancet; 2017 Jun; 389(10087):2415-2429. PubMed ID: 27939064
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment combinations for HER2-positive breast cancer.
    Pegram M
    Oncology (Williston Park); 2013 Apr; 27(4):258, 260. PubMed ID: 23781688
    [No Abstract]   [Full Text] [Related]  

  • 38. Looking Deep Into the Heterogeneity of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Can We Understand It Better?
    Loi S; Savas P
    J Clin Oncol; 2016 Feb; 34(6):521-3. PubMed ID: 26755511
    [No Abstract]   [Full Text] [Related]  

  • 39. Prognosis of t1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas.
    Cabel L; Péron J; Cottu PH; Rodrigues MJ
    J Clin Oncol; 2015 Jan; 33(3):291. PubMed ID: 25512462
    [No Abstract]   [Full Text] [Related]  

  • 40. Preoperative chemotherapy plus lapatinib or trastuzumab or both in HER2-positive operable breast cancer (CHERLOB Trial).
    Guarneri V; Frassoldati A; Piacentini F; Jovic G; Giovannelli S; Oliva C; Conte P
    Clin Breast Cancer; 2008 Apr; 8(2):192-4. PubMed ID: 18621618
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.